SCHEMBL4818876

SCHEMBL4818876

O=S(=O)(Cc1ccccc1)c1ccc(Cl)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.62
HSD17B10 Q99714 1/20 0.62
MAPT P10636 1/20 0.51
MMP2 P08253 1/20 0.51
ALDH1A1 P00352 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
HSD11B1 P28845 2/20 0.50
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
GAA P10253 1/20 0.50
PSEN1 P49768 1/20 0.49
PSEN2 P49810 1/20 0.49
APH1B Q8WW43 1/20 0.49
NCSTN Q92542 1/20 0.49
APH1A Q96BI3 1/20 0.49
PSENEN Q9NZ42 1/20 0.49
SOD1 P00441 1/20 0.49
KMT2A Q03164 2/20 0.48
NPC1 O15118 2/20 0.48
MEN1 O00255 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9820015 0.92 MAPT (0.61) TSHRHSD17B10MAPTALDH1A1SMN1; SMN2
SCHEMBL23803109 0.90 PSEN1 (0.53) TSHRHSD17B10MAPTALDH1A1LMNA
Benzylsulfonylbenzene SCHEMBL780337 0.85 TSHR (0.68) TSHRHSD17B10MAPTMMP2ALDH1A1
SCHEMBL9471604 0.84 MLNR (0.60) TSHRHSD17B10MAPTALDH1A1SMN1; SMN2
Benzylsulfonylbenzene SCHEMBL1877584 0.83 TSHR (0.66) TSHRHSD17B10MAPTMMP2ALDH1A1
SCHEMBL28544698 0.81 NPC1 (0.45) TSHRHSD17B10MAPTALDH1A1SMN1; SMN2
SCHEMBL1632268 0.81 HTT (0.53) ALDH1A1PSEN1PSEN2APH1BNCSTN
SCHEMBL4820396 0.81 GAA (0.59) ALDH1A1SMN1; SMN2HSD11B1LMNATP53
SCHEMBL30963220 0.81 MEN1 (0.60) TSHRALDH1A1LMNAGAAPSEN1
SCHEMBL4772848 0.81 PSEN1 (0.63) MAPTALDH1A1LMNATP53PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109761863-B (E) - (2- (phenylsulfonyl) ethenyl) benzene and its derivative and synthetic method 湘潭大学 2020-10-02 CN claimed
CN-109761863-A (E)-(2-(phenyl sulfonyl) vinyl) benzene and its derivative and synthetic method 湘潭大学 2019-05-17 CN claimed
CN-109761863-B (E) - (2- (phenylsulfonyl) ethenyl) benzene and its derivative and synthetic method 湘潭大学 2020-10-02 CN disclosed
CN-109761863-A (E)-(2-(phenyl sulfonyl) vinyl) benzene and its derivative and synthetic method 湘潭大学 2019-05-17 CN disclosed
US-7399775-B2 β-amyloid protein production/secretion inhibitor DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-07-15 US disclosed
US-7399775-B2 β-amyloid protein production/secretion inhibitor DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-07-15 US disclosed
US-7399775-B2 β-amyloid protein production/secretion inhibitor DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-07-15 US disclosed
US-20070293495-A1 BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-12-20 US disclosed
US-20070293495-A1 BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-12-20 US disclosed
US-20070293495-A1 BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-12-20 US disclosed
CN-100339365-C Preparation method of 3-amino-4-alkylamino methyl sulfone UNIV ZHEJIANG (CN) 2007-09-26 CN disclosed
US-20050234109-A1 to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine DAIICHI PHARMACEUTICAL CO. LTD. (JP) 2005-10-20 US disclosed
EP-1466898-A1 BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-10-13 EP disclosed
EP-0182299-B1 A CURABLE FLUOROELASTOMER COMPOSITION Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1991-04-03 EP disclosed
US-4748208-A FLUOROPOLYMER, BIS/PHOSPHINE/IMINIUM HALIDE, POLYHYDROXY CURING AGENT ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1988-05-31 US disclosed
EP-0182299-A2 A curable fluoroelastomer composition Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1986-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234109-A1 to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine APP, PSEN1, PSEN2 TSHR 2307/4885HSD17B10 1400/4885MAPT 11/4885
US-20070293495-A1 BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS APP, IAPP, BACE1 TSHR 2368/4885HSD17B10 1022/4885MAPT 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.